BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Holdings Increased by Capital Research Global Investors

Capital Research Global Investors boosted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 34.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,526,747 shares of the company's stock after purchasing an additional 912,439 shares during the period. Capital Research Global Investors owned about 1.87% of BridgeBio Pharma worth $96,774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Gabelli Funds LLC acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth approximately $2,017,000. XTX Topco Ltd purchased a new position in BridgeBio Pharma during the fourth quarter valued at $366,000. Summit Investment Advisors Inc. grew its position in shares of BridgeBio Pharma by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,706 shares of the company's stock valued at $404,000 after purchasing an additional 466 shares during the period. Sterling Capital Management LLC increased its stake in shares of BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after purchasing an additional 1,514 shares in the last quarter. Finally, F M Investments LLC purchased a new position in BridgeBio Pharma in the 4th quarter valued at about $2,667,000. Institutional investors and hedge funds own 99.85% of the company's stock.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the company's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total value of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares of the company's stock, valued at $634,841,604.16. This represents a 23.75 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the sale, the insider now directly owns 22,055,375 shares of the company's stock, valued at $769,732,587.50. The trade was a 12.20 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,769,739 shares of company stock valued at $329,866,901 over the last three months. 24.66% of the stock is owned by company insiders.

BridgeBio Pharma Price Performance

NASDAQ:BBIO traded up $0.35 during trading hours on Friday, reaching $36.31. 1,285,917 shares of the company were exchanged, compared to its average volume of 2,272,939. The firm has a market cap of $6.89 billion, a price-to-earnings ratio of -12.74 and a beta of 1.08. The stock has a 50 day simple moving average of $33.92 and a 200 day simple moving average of $30.42. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. On average, analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BBIO has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a report on Monday, March 24th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $95.00 target price on shares of BridgeBio Pharma in a report on Friday, February 21st. HC Wainwright boosted their target price on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Citigroup lifted their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Scotiabank raised their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $53.00.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.